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Introduction  
Langerhans cell histiocytosis (LCH) is characterized by the proliferation of S100 protein, 
CD1a and Langerin positive cells containing electron-microscopically detectable Birbeck 
granules. These cells resemble or are similar to epidermal antigen presenting dendritic 
Langerhans cells (LC) and thought to be derived from hematopoietic, histocytic precursors or 
from LCs. 
1-8 LCH is a rare disease, the incidence of childhood and adult forms is estimated 
to 1-9 per million but the number of adult cases is significantly lower. 
4, 7-9 The clinical 
appearance of LCH is highly variable, it can develop at any age and in almost any organ. 
According to the recommendation of the „Histiocytic Society” LCH can be classified into 
three main forms depending on the involved organs: single system disease and multisystem 
disease with or without “risk organ” (lung, liver, spleen, hematopoetic) dysfunction. 1, 7-11 
Cutaneous involvement is frequently present in LCH. Skin manifestation is more common in 
children, but numerous adult patients are also presented with skin lesions. 
9, 12 As up to  
30-80% of LCH patients develop skin symptoms, the diagnosis is frequently provided by 
histopathological examination of the skin biopsy. 
1, 7, 12  
The prognosis depends on the dissemination of the disease, the presence or absence of organ 
dysfunction, the patient’s age of onset and the response to the initial therapy. 
The etiology and pathogenesis of the disease has not been fully understood yet, and even the 
fact whether LCH is a true malignant or a reactive, inflammatory process has been debated in 
the literature. 
2-4, 6-9 Recently, however a new possible molecular genetic background has 
been suggested with the demonstration of the activating, oncogenic BRAFV600E gene 
mutation in a subset (38-68%) of LCH samples. This strongly supports the neoplastic origin 
of the disease. 
2, 3, 5, 6, 13, 14  
Our first aim was to collect adult onset LCH patients and to analyze the characteristics of their 
disease. The second goal of our study was to detect the presence and rate of BRAFV600E 
mutation solely from skin lesions. Previous literature data evaluated the incidence of this 
mutation in all kinds of LCH lesions, but among the analyzed samples the ratio of skin lesion 
was relatively low. Based on the presented data it can be estimated that so far approximately 
not more than 30 skin samples were examined. 
3, 5, 13-15 As skin is a frequently involved 
organ and is an easily accessible site for biopsy to establish the histopathological diagnosis of  
LCH patients it is very important to obtain data on the availability of BRAF mutation status in 
such samples too. 
1, 7, 12  
 
Materials and methods 
Patients and samples 
Fifteen adult LCH patients were diagnosed and treated between 1987 and 2012 at the 
Department of Dermatology and Allergology, Albert Szent-Györgyi Clinical Center 
University of Szeged, Hungary. Clinical and treatment characteristics of the patients are 
summarized in Table 1 and 2.   
The available archived formalin fixed paraffin embedded blocks were also retrieved. Eleven 
skin samples from 10 LCH patients could be examined. One patient had two biopsies (a 
punch biopsy and an excision) of the trunk’s skin in one month interval to establish the 
diagnosis. (Table 2) The other 5 patients’ skin samples were also examined at our department 
earlier, but the samples originated from other laboratories and the paraffin blocks were sent 
back after examination and were not available for our current analysis. 
 
BRAF V600 mutation detection 
Five m sections were obtained from formalin-fixed paraffin-embedded tissue biopsy 
specimens. After deparaffinization genomic DNA samples were isolated using the cobas® 
DNA Sample Preparation Kit (Roche Molecular Systems Inc., Roche Molecular Diagnostics, 
Branchburg, New Jersey, USA) according to the users’ manual. BRAFV600E mutation was 
detected on the cobas z 480 Analyzer with the cobas® 4800 BRAF V600 Mutation Test 
(Roche Molecular Systems Inc., Roche Molecular Diagnostics, Branchburg, New Jersey, 
USA)  following the instructions of the manufacturer. 
 
Results 
The development of skin symptoms drew the attention to the underlying LCH in most of our 
15 LCH patients. The male:female ratio was 5:10 (1:2), the median age at the time of the 
presentation of the skin lesions was 56 years (age range 24 to 91 years). Three patients had 
single system disease, exhibiting only skin symptoms, whereas 12 patients suffered from 
multisystem disease with or without organ dysfunction. Diabetes insipidus was present in 6 
patients, the lymphoreticular system was affected in 9 cases and 1 patient had idiopathic 
thrombocytopenic purpura. Four patients had pulmonary involvement and 3 patients 
developed bone lesions.   
Most of the skin lesions were papules, plaques and nodules, situated at the predilection sites. 
The flexural areas and the head were involved in most cases and 3 patients suffered from 
genital skin lesions. Thirteen patients had more than one affected region. Pruritus, erosion and 
ulceration also complicated the lesions very frequently. (Figure 1) Clinical data are shown in 
Table 1. Diagnosis was confirmed by the examination of skin biopsy specimens, showing the 
characteristic microscopic morphology and the proliferation of CD1a positive cells. (Figure 2) 
BRAF mutation detection was performed in 11 skin samples from 10 LCH patients (patient 
N° 15 had two biopsies).  Among the 11 samples 6 contained BRAFV600E mutation which 
represents 54.5 %. Although the case number in our study is relatively low and two BRAF 
positive biopsies came from one patient (patient N° 15), we can conclude that approximately 
half of the examined samples contained the mutation.  
Two of our BRAF positive patients with multisystem disease died. One of them died in spite 
of a combined therapy whereas the other patient refused treatment. The remaining 3 patients 
positive for the examined BRAF mutation also had a multisystem disease with organ 
dysfunction and they showed significant improvement or became symptom-free upon topical 
and/or systemic steroid treatment and supportive therapy for diabetes insipidus. (Table 2, 
Figure 3) 
Two patients died of the disease in the BRAF negative group suffering from the multisystem 
form of the disease. The remaining 3 patients in the same group improved in response to the 
treatment, even though 2 of them had multisystem involvement with organ dysfunction, 
whereas the third patient had a single system disease affecting only the skin. Although our 
case number is too low to draw statistical conclusions, our observations strongly suggest that 
the BRAF mutation status may not correlate with the extent and/or the outcome of this 
disease. 
 
Discussion 
The clinical manifestation of LCH’s is highly variable. Almost any organ can be involved and 
the disease can develop at any age. Childhood cases are thought to have a tendency to be 
multisystem disease whereas adult patients are more prone to develop a single system disease, 
although there are some controversies in the literature concerning these data. 
1
  
The most frequently involved organs are the bone (which is also the most common site of the 
single system disease), skin, pituitary gland (leading to the development of diabetes 
insipidus), liver, spleen, lung, bone marrow. 
1, 7, 9  
Cutaneous involvement can be frequently present in the affected individuals. According to the 
available literature, 30-80% of the patients develop skin symptoms and it is often the skin 
biopsy that provides the histopathological diagnosis. 
1, 7, 12 Although skin manifestation is 
more common in children, adult forms can be presented also with skin lesions. These 
symptoms can affect any part of the body but typically involve flexural, genital, perianal and 
glabrous areas. Papules, plaques, eczema-like or seborrhoeic dermatitis-like rash with scales 
and scab along with pruritus are the most common skin manifestations. 
9, 12 
Adult forms are almost similar to the childhood ones, but the single lung involvement seems 
more frequent (up to 20-30%) in adults. The isolated pulmonary disease is strongly associated 
with smoking and polyclonal LCs can be detected in these lesions quite frequently 
4, 7   
The prognosis of LCH depends on its dissemination, the presence or absence of organ 
dysfunction, the patient’s age at disease onset and the response to initial therapy. 1, 7, 8 
Patients with widespread, high-risk disease have poor prognosis with a 20-50% mortality rate 
in spite of combined therapy, 
2, 3, 7, 8, 16 and the 5-year event free survival ratio of adult 
forms is much better even in the disseminated forms. 
7
  Treatment of LCH depends mainly on 
the dissemination of the disease. Single system disease – mainly bone lesions - frequently 
requires surgical removal (curettage) maybe combined with intralesional steroids while 
multisystem forms, even with organ dysfunction needs combined chemotherapy (vinblastine, 
methotrexate) and/or prednison. 
1, 4, 7-9, 16 Localized cutaneous lesions can be treated with 
topical steroid or tacrolimus while disseminated skin disease can improve upon thalidomide, 
interferon, PUVA, or methotrexate and chemotherapy. 
7, 9, 10 Treatment of LCH in adults is 
more challenging than in childhood because experience is more limited due to the low 
incidence in this age group. 
16
  
The etiology and exact pathogenesis of this disease is still not fully understood. It has been 
debated in the literature whether LCH is a true malignant or a reactive, inflammatory process. 
2-4, 6-9 It has been suggested that LCH is a clonal disease although there is a significant 
inflammatory component in the infiltrate (eosinophils, macrophages, lymphocytes, giant cells) 
with elevated levels of cytokins and chemokins. 
3, 4, 9  
The recent demonstration of the activating, oncogenic BRAFV600E gene mutation in 38-68% 
of LCH samples and the fact that the neoplastic LC cases often carry this mutation strongly 
supports the neoplastic origin of the disease. 
2, 3, 5, 6, 13, 14 Recent data suggest that there is 
an activation of the RAS-RAF-MEK pathway in the background of LCH but in BRAF 
negative cases however the precise activating factors are not known yet. 
4, 6, 9 Better 
understanding of the molecular background of the disease is very important because in 
disseminated and treatment refractory cases the possibility of a new targeted therapy based on 
molecular pathology can be a promising option in the therapeutic repertoire. It has also been 
demonstrated that among other histiocytic disorders (both neoplastic and reactive conditions) 
only nearly half of Erdheim-Chester diseases carry the same BRAF mutation. 
13
 There is even 
a recent report on effective vemurafenib treatment in disseminated combined Erdheim-
Chester disease and LCH carrying the BRAFV600E mutation. 
15
 
17, 18 
 In the present work we were able to prove the presence of the BRAFV600E mutation in 6 
among 11 LCH skin samples (54.5 %). The frequency of BRAF V600E mutation in our series 
correlates well with the initial data of Badalian-Very et co-workers (57%) 
3
 and the recent 
study of Satoh and his colleagues (68%), 
14
 whereas was higher than the results demonstrated 
by two other authors’ Sahm 5 and Haroche and their groups (38%). 13   
It should be also emphasized that the previous studies analyzed the BRAF mutation status 
from lesions of various anatomical sites (bone, lung, etc.) and only a few cutaneous lesions 
were involved in these studies. Ours is the first one that was focusing especially to skin LCH 
lesions. Taking into account the literature  data of  57% BRAF positivity in various LCH 
lesions 
3
, our results strongly suggest that skin lesions of LCH are eligible for the diagnosis of 
the disease and for the assessment of the BRAF mutation status, too. Knowing the high 
proportion of skin involvement in LCH patients this observation highlights the importance of 
skin biopsy as an easily accessible diagnostic material.  
According to the previous data it was suspected that the presence of this particular BRAF 
mutation might correlate with younger age, 
3, 4 
19
 but another studies could not prove this 
hypothesis. 
14
 The results on our adult group of LCH patient however, strongly suggest that 
the occurrence of BRAF V600E mutation can be as frequent in childhood as in the adult 
forms at least as far as skin lesions are concerned.  Although the case number in our study is 
too low to make statistical analysis, our observations also suggest that the BRAF mutation 
status may not present a clear correlation with the extent and/or the outcome of the disease. 
 
Conclusion 
Our results support the neoplastic origin of LCH and correlates well with the previous data on 
BRAFV600E mutation ratio in this rare disease. These data suggest that the occurrence of the 
mutation in adult forms can be as frequent as in childhood cases, and underline the 
importance of the early recognition of skin symptoms and the high impact of skin biopsy in 
the diagnosis of the disease. Currently it is not clear whether the carriage of the BRAF 
mutation has any effect on the extent and/or the outcome of the disease, and further studies 
are required to answer these questions. However, our results underlie the importance of 
molecular pathway analyses that can potentially lead to the administration of promising new 
targeted therapies in affected individuals, providing better disease control and prognosis for 
the LCH patients. 
15
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 Figure 1. 
 
Various skin lesions in LCH: a) erythematous plaques on the trunk – Patient 10, b) erosions 
on the vulva – Patient 8, c) scaling papules and plaques on the nose – Patient 13. 
(Patient number refers to Table1.) 
 
 Figure 2 
 
 
The characteristic histopathological picture of skin lesion in LCH – Patient 15. a) HE, b) 
CD1a staining 
 
 
 
 Figure 3 
 
Significant improvement upon systemic steroid and methotrexate treatment in Patient 9. 
 
 
 
 
Table 1. 
 
 
Patient 
Age/ 
gender 
Skin Systemic involvement Treatment 
Outcome  
Head 
Flexural 
areas 
Glabrous 
areas 
Genital 
area 
Skin 
symptoms  
Bone Lung 
Endocrine 
system 
Lympho
reticular 
system 
Surgery 
Topical 
steroid 
Systemic 
steroid 
PUVA 
Cytostatic 
drugs 
1. 24/♀ - + - - 
Pruritus, 
papules 
- - - - - + - - - Improved  
2. 40/♀ - + + - 
Pruritus, 
papules,  
nodules 
+ + - + + + + - - Improved   
3. 82/♀ + + + - 
Pruritus, 
papules,  
plaques, 
erosions 
- - - + - + - - - Deceased 
4. 47/♀ - - + + 
indurated, 
ulcerated 
plaques, 
nodules 
- - - - + + - - - Improved  
5. 72/♂ + + + - 
Pruritus, 
erythema,
plaques, 
scaling 
- + - + - + + - + Deceased 
6. 68/♀ - + + - 
Papules, 
plaques,  
Erosions 
- - 
+ 
Diabetes 
insipidus 
+ - + + - + Deceased  
7. 91/♀ - + + - 
Pruritus, 
papules 
+ - - - - - - -/+ - Deceased  
8. 51/♀ - - - + 
Erosion of 
the vulva,  
ulcer of 
the oral 
mucosa 
+ - 
+ 
Diabetes 
insipidus 
- - + + - - Improved  
9. 36/♂ + + + + 
Papules, 
plaques,  
Erosions 
- + 
+ 
Diabetes 
insipidus 
+ - - + - + Improved   
 10. 50/♂ - + + - 
Pruritus, 
erythema, 
plaques, 
nodules 
- - 
+ 
Diabetes 
mellitus 
+ - + - - + Improved  
11. 65/♀ + + + - 
Erythema, 
plaques, 
Erosion 
- - - 
+ 
ITP 
- + + - - Improved  
12. 66/♀ - + + - 
“burning” 
tongue, 
ulcer of 
the oral 
mucosa 
papules 
- - 
+ 
Diabetes 
insipidus 
- - + - - - Improved  
13. 56/♂ + - + - 
Papules, 
nodules, 
erosions 
- + 
+ 
Diabetes 
insipidus 
+ - + - - + Improved  
14. 54/♀ + - + - 
Pruritus, 
papules 
pustules 
- - - - - + + - + Impoved 
15. 
71/♂ 
2 bx 
+ + + - 
Pruritus, 
papules, 
pustules, 
erosions 
- - - 
Hepato- 
spleno- 
megaly 
- + - - - Deceased  
 
Table 1.: Clinical data, treatment and outcome of the 15 adult LCH patients  
  
Table 2. 
 
 
Patient No 
BRAF 
mutation 
Multisystem disease Treatment  Outcome 
5. NO 
yes, with organ 
dysfunction 
topical and systemic steroid, 
cytostatic drugs 
deceased 
6. YES 
yes, with organ 
dysfunction 
topical and systemic steroid, 
cytostatic drugs 
deceased 
7. NO yes PUVA deceased 
8. YES 
yes, with organ 
dysfunction 
topical and systemic steroid improved 
9. NO 
yes, with organ 
dysfunction 
systemic steroid, cytostatic 
drugs 
improved 
10. NO 
yes, with organ 
dysfunction 
topical steroid, cytostatic drugs improved 
11. YES 
yes, with organ 
dysfunction  
topical and systemic steroid improved 
12. YES 
yes, with organ 
dysfunction 
topical steroid improved 
14. NO no 
topical and systemic steroid, 
cytostatic drugs 
improved 
15. (2 bx) 
YES 
YES 
yes, with organ 
dysfunction 
no treatment deceased 
 
Table 2.: BRAF mutation status of 11 lesions from 10 patients with their disease type, 
treatment modalities and outcomes 
Patient No refers to patient’s numbers in Table1. 
 
 
 
 
